NO20052203D0 - Anvendelse av cytokin som kan binde IL-18BP og inhibere aktiviteten til et andre cytokin - Google Patents

Anvendelse av cytokin som kan binde IL-18BP og inhibere aktiviteten til et andre cytokin

Info

Publication number
NO20052203D0
NO20052203D0 NO20052203A NO20052203A NO20052203D0 NO 20052203 D0 NO20052203 D0 NO 20052203D0 NO 20052203 A NO20052203 A NO 20052203A NO 20052203 A NO20052203 A NO 20052203A NO 20052203 D0 NO20052203 D0 NO 20052203D0
Authority
NO
Norway
Prior art keywords
cytokine
bind
inhibit
activity
mutein
Prior art date
Application number
NO20052203A
Other languages
English (en)
Other versions
NO337024B1 (no
NO20052203L (no
Inventor
Charles Dinarello
Soo-Hyun Kim
Philip Bufler
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20052203D0 publication Critical patent/NO20052203D0/no
Publication of NO20052203L publication Critical patent/NO20052203L/no
Publication of NO337024B1 publication Critical patent/NO337024B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
NO20052203A 2002-10-08 2005-05-04 Anvendelse av cytokin-1 IL-1F7b som kan binde IL-18BP, for fremstilling av et medikament for behandling eller forebygging av inflammatoriske sykdommer, samt en vektor som koder for nevnte cytokin og anvendelse av nevnte vektor NO337024B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41682702P 2002-10-08 2002-10-08
PCT/US2003/031378 WO2004032837A2 (en) 2002-10-08 2003-10-03 The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine

Publications (3)

Publication Number Publication Date
NO20052203D0 true NO20052203D0 (no) 2005-05-04
NO20052203L NO20052203L (no) 2005-05-04
NO337024B1 NO337024B1 (no) 2016-01-04

Family

ID=32093906

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052203A NO337024B1 (no) 2002-10-08 2005-05-04 Anvendelse av cytokin-1 IL-1F7b som kan binde IL-18BP, for fremstilling av et medikament for behandling eller forebygging av inflammatoriske sykdommer, samt en vektor som koder for nevnte cytokin og anvendelse av nevnte vektor

Country Status (15)

Country Link
US (2) US7279155B2 (no)
EP (1) EP1572291B1 (no)
JP (1) JP4563813B2 (no)
KR (1) KR101015682B1 (no)
CN (1) CN1909926A (no)
AU (1) AU2003299919B2 (no)
BR (1) BR0315155A (no)
CA (1) CA2500577C (no)
EA (1) EA008667B1 (no)
ES (1) ES2416510T3 (no)
IL (1) IL167769A (no)
MX (1) MXPA05003869A (no)
NO (1) NO337024B1 (no)
UA (1) UA86750C2 (no)
WO (1) WO2004032837A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335336B (no) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
UA86750C2 (ru) * 2002-10-08 2009-05-25 Арес Трейдінг С.А. Применение il-1f7b, способного связываться с il-18r и il-18bp, вместе с il-18bp для лечения заболеваний, ассоциированных с избыточной активностью il-18
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2006081190A2 (en) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
US8557745B2 (en) * 2007-05-22 2013-10-15 Janssen Biotech, Inc. Markers and methods for assessing and treating Crohn's and related disorders
MX2017010919A (es) * 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
US11524985B2 (en) * 2017-03-20 2022-12-13 Bio-Techne Corporation IL-37 fusion protein and methods of making and using same
US20190070262A1 (en) * 2017-09-06 2019-03-07 Yale University Interleukin-18 variants and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
UA42675C2 (uk) 1989-12-22 2001-11-15 Апплайд Рєзєч Сістемз, Арс Холдінг Н.В. (Антільські Острови) Спосіб активації гена, що в нормі транскрипційно мовчить, з геному еукаріотичної клітинної лінії, спосіб модифікації характеристик експресії гена з геному еукаріотичної клітинної лінії, диференційована еукаріотична клітинна лінія (варіанти), днк-конструкт
EP0554381B2 (en) * 1990-10-25 2000-04-26 Genentech, Inc. Use of protective agents against reactive oxygen species
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
US5945310A (en) * 1997-05-19 1999-08-31 Smithkline Beecham Corporation DNA encoding members of the IL-1 family, IL-1 delta
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) * 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
ES2226335T3 (es) * 1998-01-23 2005-03-16 Immunex Corporation Receooctires de uk.18.
US6342371B1 (en) 1999-04-16 2002-01-29 Smithkline Beecham Corporation Interleukin-1 homologue, IL-1H4
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
WO2001040247A1 (en) * 1999-12-01 2001-06-07 Smithkline Beecham Corporation Interleukin-1 homologue, mat il-1h4
AU2002224417A1 (en) 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
UA86750C2 (ru) * 2002-10-08 2009-05-25 Арес Трейдінг С.А. Применение il-1f7b, способного связываться с il-18r и il-18bp, вместе с il-18bp для лечения заболеваний, ассоциированных с избыточной активностью il-18

Also Published As

Publication number Publication date
CA2500577A1 (en) 2004-04-22
US20090074710A1 (en) 2009-03-19
EA008667B1 (ru) 2007-06-29
WO2004032837A3 (en) 2006-04-13
EP1572291A2 (en) 2005-09-14
US20040120923A1 (en) 2004-06-24
CA2500577C (en) 2013-12-17
US7279155B2 (en) 2007-10-09
EP1572291A4 (en) 2009-06-24
IL167769A (en) 2013-10-31
AU2003299919B2 (en) 2009-08-06
BR0315155A (pt) 2005-08-16
JP2006516953A (ja) 2006-07-13
CN1909926A (zh) 2007-02-07
UA86750C2 (ru) 2009-05-25
ES2416510T3 (es) 2013-08-01
AU2003299919A1 (en) 2004-05-04
WO2004032837A2 (en) 2004-04-22
EA200500617A1 (ru) 2006-08-25
KR20050074470A (ko) 2005-07-18
JP4563813B2 (ja) 2010-10-13
MXPA05003869A (es) 2005-06-22
US7820156B2 (en) 2010-10-26
NO337024B1 (no) 2016-01-04
EP1572291B1 (en) 2013-04-03
KR101015682B1 (ko) 2011-02-22
NO20052203L (no) 2005-05-04

Similar Documents

Publication Publication Date Title
NO20052203D0 (no) Anvendelse av cytokin som kan binde IL-18BP og inhibere aktiviteten til et andre cytokin
DK1651615T3 (da) Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
NO20062148L (no) Antistoffer som binder interleukin-4-reseptor
ATE475673T1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
BRPI0313733A8 (pt) Uso da proteína n beta cinase
DK1784426T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
HUP0301789A2 (hu) Rekombináns anti CD40 ellenanyagok és használatuk
NO20054959D0 (no) Fremgangsmater for behandling av interleukin-6 relaterte sykdommer
NO20070087L (no) Anti-IL-13 antistoffer, krystaller av anti-IL-13 antistoffer og komplekser omfattende dem
DK2230308T3 (da) Antistofmolekyle, der har specificitet for human tumornekrosisfaktor-alfa, og anvendelse deraf
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
TW200709817A (en) Platform antibody compositions
RS51755B (en) USE OF IL-18 INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF PERIPHERAL VASCULAR DISEASES
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
CY1112673T1 (el) Φαινοξυ αιθερες αμινοξεων
DK1851236T3 (da) Makrolider med anti-inflammaterisk virkning
IL178478A0 (en) Pharmaceutical compositions containing anti-cd-3 antibodies
ES2340842T3 (es) Anticuerpos anti-apc no neutralizantes.
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
NO20060196L (no) Antranilamidpyridoner som inhiberer VEGFR-2 og VEGFR-3
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.
NO20051938L (no) Promoter til IL-18BP, dens fremstilling og anvendelse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees